HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbalife

This article was originally published in The Tan Sheet

Executive Summary

U.S. retail sales rose 29.3% to $122.7 mil. for the first quarter, firm announces April 28. North and South American retail sales increased 32.2% to $160.1 mil. Worldwide performance was up only 6.9% due to sinking retail sales in Asia/Pacific Rim (down 4% to $185.6 mil.) and Europe (down 6% to $122.7 mil.). However, European retail sales improved 9% in local currency. Excluding distributor allowances, net sales grew 7.8% to $244 mil., compared to the prior-year period. Net income was flat at $11.6 mil. due to a $5.9 mil. charge related to the failure of CEO Mark Hughes' plan to buy back company's shares and take the firm private (1"The Tan Sheet" Sept. 20, 1999, p. 15)

You may also be interested in...



Herbalife CEO To Purchase All Remaining Stock, Take Company Private

Herbalife International CEO and founder Mark Hughes will be buying all the company's remaining Class A and Class B shares, the firm announced Sept. 13.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS133793

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel